Compare YDES & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YDES | TRIN |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | YDES | TRIN |
|---|---|---|
| Price | $11.97 | $15.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 110.9K | ★ 723.7K |
| Earning Date | 09-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 13.50% |
| EPS Growth | N/A | ★ 25.79 |
| EPS | N/A | ★ 2.17 |
| Revenue | $510,360.00 | ★ $268,271,000.00 |
| Revenue This Year | N/A | $29.07 |
| Revenue Next Year | N/A | $13.52 |
| P/E Ratio | ★ N/A | $6.98 |
| Revenue Growth | ★ 45.76 | 30.76 |
| 52 Week Low | $5.30 | $12.50 |
| 52 Week High | $31.00 | $16.82 |
| Indicator | YDES | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.79 |
| Support Level | N/A | $14.47 |
| Resistance Level | N/A | $15.29 |
| Average True Range (ATR) | 0.00 | 0.22 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 84.68 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.